Home / Business / Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer

San Diego CA— Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, infectious, fibrotic, and respiratory diseases with significant unmet medical need, today announced that the Company has appointed Andrew Sassine as Chief Financial Officer (CFO), effective January 1, 2019. Mr. Sassine has been serving as Arcturus’ Interim Chief Financial Officer since August 2018 and has served on the Company’s Board of Directors since May 2018.

“Andy has already made meaningful contributions, both as Interim CFO and as a board member, and we are delighted to confirm his appointment as CFO,” said Joseph Payne, President & CEO of Arcturus Therapeutics. “Andy’s cross-industry experience counseling life sciences companies, as well as his experience as an institutional investor have provided him with the skillset and depth of knowledge to manage our financial affairs and help create value for our various stakeholders as we continue to innovate and advance our pipeline of RNA medicines.”

“My involvement so far with Arcturus has convinced me that Arcturus has the capabilities to become a major player in the development of RNA based therapeutics.  It is an honor to be named CFO,” said Mr. Sassine. “I look forward to continuing my work with such a talented team to achieve Arcturus’ financial and strategic objectives.”

In addition to serving on the Arcturus board, Mr. Sassine serves on the boards of iCAD, Inc.

(NASDAQ: ICAD), a provider of advanced image analysis, workflow solutions and radiation therapy for the early detection and treatment of cancer, and Gemphire Therapeutics (NASDAQ: GEMP), a clinical-stage biopharma company focused on therapies for the treatment of dyslipidemia. Previously, Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, most recently as portfolio manager. Mr. Sassine received a B.A. from the University of Iowa in 1987 and an M.B.A. from the Wharton School at the University of Pennsylvania in 1993.


About Arcturus Therapeutics Ltd.

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Ltd. (NASDAQ: ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR® lipid-mediated delivery. Arcturus’ diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (140 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’ commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., CureVac AG and the Cystic Fibrosis Foundation. For more information, visit www.Arcturusrx.com, the content of which is not incorporated herein by reference.